Overview

A Study of TAK-279 in Adults With or Without Kidney Problems

Status:
Active, not recruiting
Trial end date:
2024-05-28
Target enrollment:
Participant gender:
Summary
The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with kidney problems compared to participants without kidney problems. Other aims are to check for side effects from TAK-279 and to learn how well participants tolerate 1 dose of TAK-279. The participants will need to stay at the clinic for 11 days.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda